BNP Paribas Has $9.43 Million Stake in Boston Scientific Corporation $BSX

BNP Paribas trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 16.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 94,114 shares of the medical equipment provider’s stock after selling 18,141 shares during the period. BNP Paribas’ holdings in Boston Scientific were worth $9,433,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Steph & Co. bought a new stake in shares of Boston Scientific during the 3rd quarter worth $25,000. Financial Consulate Inc. acquired a new position in Boston Scientific in the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp raised its holdings in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth $26,000. Finally, United Community Bank boosted its holdings in Boston Scientific by 115.7% during the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 147 shares during the period. Institutional investors own 89.07% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on BSX shares. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Robert W. Baird decreased their target price on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $108.00.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Stock Up 0.9%

BSX stock opened at $69.15 on Friday. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The company has a market cap of $102.61 billion, a PE ratio of 35.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The business’s 50-day simple moving average is $82.47 and its 200 day simple moving average is $93.29.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the company earned $0.70 EPS. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.